Lv2
110 积分 2025-05-09 加入
Molecular Evidence of Multiorgan Damage in Patients with Immune-Related Adverse Events
5天前
已完结
The Phase II MutHER Study of Neratinib Alone and in Combination with Fulvestrant in HER2-Mutated, Non-amplified Metastatic Breast Cancer
1个月前
已完结
AI-driven biomarkers for antibody-drug conjugates
1个月前
已完结
Biomarkers for Antibody–Drug Conjugates in Solid Tumors
1个月前
已完结
Biomarkers for Antibody-Drug Conjugates in Solid Tumors
1个月前
已关闭
HER2 testing: evolution and update for a companion diagnostic assay
1个月前
已完结
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
1个月前
已完结
Towards multimodal foundation models in molecular cell biology
1个月前
已完结
Navigating established and emerging biomarkers for immune checkpoint inhibitor therapy
1个月前
已完结
HER2DX and survival outcomes in early-stage HER2-positive breast cancer: an individual patient-level meta-analysis
2个月前
已完结
皖公网安备34019202002308
